4D Molecular Therapeutics(US:FDMT) Financial Modeling Prep·2026-03-19 18:00Core Insights - 4D Molecular Therapeutics, Inc. reported a strong Q4 2025 EPS of $0.43, a significant improvement from the expected loss of -$0.53, driven by one-time collaboration revenue [3][6] - The full-year 2025 results showed a narrowed net loss of $140 million, improving from a loss of $161 million in 2024 [3] - Revenue for full-year 2025 was $85 million, primarily from Q4 collaboration, indicating growth potential from partnerships [4] Financial Performance - Q4 2025 revenue was $85.09 million, exceeding expectations by approximately 147.86%, mainly due to an $85 million upfront collaboration payment from Otsuka Pharmaceutical [6] - The company maintains a strong balance sheet with a low debt-to-equity ratio of ~0.042 and a high current ratio of ~9.39 [5] - As of December 31, 2025, the company had $514 million in cash, cash equivalents, and marketable securities, providing financial stability into the second half of 2028 [5] Industry Context - 4D Molecular Therapeutics operates in the Zacks Medical - Drugs industry, competing in the gene therapy space [2] - The company's performance highlights the potential for growth in gene therapy partnerships, although sustainability will depend on pipeline progress and future milestones [4]